Lupin's Subsidiary Reaches Settlement in Major Antitrust Litigation
Lupin Pharmaceuticals, Inc. USA (LPI), a wholly owned subsidiary of Lupin Limited, has entered into a Settlement Agreement with Humana Inc., one of the plaintiffs involved in multiple civil lawsuits. The settlement resolves allegations concerning anticompetitive behavior and violations of federal and state antitrust laws.The multiple civil lawsuits were combined into a collection of similar cases known as In Re Generic Pharmaceuticals Antitrust Litigation, located in Philadelphia, Pennsylvania. While LPI denies all allegations, the company proceeded with the settlement agreement with Humana Inc. in order to avoid the costs and uncertainties associated with continued litigation, especially given that other defendants have recently settled their respective cases.
Under the terms of the Agreement, LPI will pay a settlement amount to Humana Inc. The financial details of the settlement are as follows:
| Party Making Payment | Party Receiving Payment | Settlement Amount |
|---|---|---|
| LPI | Humana Inc. | USD 30 million |
The payment of USD 30 million provides a full and final release of all claims against LPI and its current and former parents, affiliates, directors, employees, and officers by Humana.
Lupin Limited confirmed that this settlement amount has already been incorporated into the company's prior consolidated financial results. The agreement explicitly states that LPI denies all allegations made against it, and the settlement does not imply any admission of liability or unlawful conduct by the company.
LUPIN Stock Price Movement
Shares of Lupin Limited on Thursday slipped by 0.59% to settle at ₹2327. The stock shed ₹13.90 during the trading session, closing on a total volume of 985,698 shares.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.